Hormonal milieu at time of B cell activation controls duration of autoantibody response

Journal of Autoimmunity

Volumn 53, Issue C, 2014, Pages 46-54

  Jeganathan, Venkatesh ^a   Peeva, Elena ^b   Diamond, Betty ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Anti DNA antibody; Autoantibodies; Autoreactive; B cells

Indexed keywords

AUTOANTIBODY; DNA; DNA ANTIBODY; ESTRADIOL; IMMUNOGLOBULIN G2B; PROLACTIN; ANTINUCLEAR ANTIBODY; IMMUNOGLOBULIN HEAVY CHAIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL DIFFERENTIATION; CONTROLLED STUDY; DNA BINDING; FEMALE; FOLLICULAR B CELL; HORMONAL REGULATION; HORMONAL THERAPY; MARGINAL ZONE B CELL; MOUSE; NONHUMAN; PATHOGENESIS; PRE B LYMPHOCYTE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSGENE; ANIMAL; BAGG ALBINO MOUSE; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, ANTINUCLEAR; B-LYMPHOCYTES; ESTRADIOL; FEMALE; IMMUNOGLOBULIN HEAVY CHAINS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; PROLACTIN;

EID: 84926410083     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2014.02.007     Document Type: Article

References (72)

1. Martin F., Kearney J.F. Marginal-zone B cells. Nat Rev Immunol 2002, 2:323-335.
2. Pillai S., Cariappa A. The follicular versus marginal zone B lymphocyte cell fate decision. Nat Rev Immunol 2009, 9:767-777.
3. Tarkowski A., Lue C., Moldoveanu Z., Kiyono H., McGhee J.R., Mestecky J. Immunization of humans with polysaccharide vaccines induces systemic, predominantly polymeric IgGA2-subclass antibody responses. JImmunol 1990, 144:3770-3778.
4. Carson P.J., Schut R.L., Simpson M.L., O'Brien J., Janoff E.N. Antibody class and subclass responses to pneumococcal polysaccharides following immunization of human immunodeficiency virus-infected patients. JInfect Dis 1995, 172:340-345.
5. Janeway C.A., Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002, 20:197-216.
6. Genestier L., Taillardet M., Mondiere P., Gheit H., Bella C., Defrance T. TLR agonists selectively promote terminal plasma cell differentiation of B cell subsets specialized in thymus-independent responses. JImmunol 2007, 178:7779-7786.
7. Rubtsov A.V., Swanson C.L., Troy S., Strauch P., Pelanda R., Torres R.M. TLR agonists promote marginal zone B cell activation and facilitate T-dependent IgM responses. JImmunol 2008, 180:3882-3888.
8. Bendelac A., Bonneville M., Kearney J.F. Autoreactivity by design: innate B and T lymphocytes. Nat Rev Immunol 2001, 1:177-186.
9. Rajewsky K. Clonal selection and learning in the antibody system. Nature 1996, 381:751-758.
10. MacLennan I.C. Germinal centers. Annu Rev Immunol 1994, 12:117-139.
11. Zheng D., Lee M.K., Tung J., Brendolan A., Strober S. Cutting edge: a role for CD1 in the pathogenesis of lupus in NZB/NZW mice. JImmunol 2000, 164:5000-5004.
12. Marion T.N., Krishnan M.R., Steeves M.A., Desai D.D. Affinity maturation and autoimmunity to DNA. Curr Dir Autoimmun 2003, 6:123-153.
13. Offen D., Spatz L., Escowitz H., Factor S., Diamond B. Induction of tolerance to an IgG autoantibody. Proc Natl Acad Sci U S A 1992, 89:8332-8336.
14. Spatz L., Saenko V., Iliev A., Jones L., Geskin L., Diamond B. Light chain usage in anti-double-stranded DNA B cell subsets: role in cell fate determination. JExp Med 1997, 185:1317-1326.
15. Bynoe M.S., Spatz L., Diamond B. Eur J Immunol 1999, 29:1304-1313.
16. Bynoe M.S., Grimaldi C.M., Diamond B. Estrogen up-regulates Bcl-2 and blocks tolerance induction of naive B cells. Proc Natl Acad Sci U S A 2000, 97:2703-2708.
17. Chapel T.A., Burns R.E. Oral contraceptives and exacerbation of lupus erythematosus. Am J Obstet Gynecol 1971, 110:366-369.
18. Travers R.L., Hughes G.R. Oral contraceptive therapy and systemic lupus erythematosus. JRheumatol 1978, 5:448-451.
19. Garovich M., Agudelo C., Pisko E. Oral contraceptives and systemic lupus erythematosus. Arthritis Rheum 1980, 23:1396-1398.
20. Barrett C., Neylon N., Snaith M.L. Oestrogen-induced systemic lupus erythematosus. Br J Rheumatol 1986, 25:300-301.
21. Roubinian J.R., Talal N., Greenspan J.S., Goodman J.R., Siiteri P.K. Effect of castration and sex hormone treatment on survival, anti-nucleic acid antibodies, and glomerulonephritis in NZB/NZW F1 mice. JExp Med 1978, 147:1568-1583.
22. Lucas J.A., Ahmed S.A., Casey M.L., MacDonald P.C. Prevention of autoantibody formation and prolonged survival in New Zealand black/New Zealand white F1 mice fed dehydroisoandrosterone. JClin Invest 1985, 75:2091-2093.
23. Vidaller A., Llorente L., Larrea F., Mendez J.P., Alcocer-Varela J., Alarcon-Segovia D. Tcell dysregulation in patients with hyperprolactinemia: effect of bromocriptine treatment. Clin Immunol Immunopathol 1986, 38:337-343.
24. McMurray R.W. Prolactin and systemic lupus erythematosus. Ann Med Intern 1996, 147:253-258.
25. Lavalle C.E., Graef A., Baca V., Ramirez-Lacayo M., Blanco-Favela F., Ortiz O. Prolactin and gonadal hormones: a key relationship that may have clinical, monitoring and therapeutic implications in systemic lupus erythematosus. Lupus 1993, 2:71-75.
26. Walker S.E., McMurray R.W., Houri J.M., Allen S.H., Keisler D., Sharp G.C., et al. Effects of prolactin in stimulating disease activity in systemic lupus erythematosus. Ann NY Acad Sci 1998, 840:762-772.
27. McMurray R.W., Weidensaul D., Allen S.H., Walker S.E. Efficacy of bromocriptine in an open label therapeutic trial for SLE. JRheumatol 1995, 22:2084-2091.
28. Allen S.H., Sharp G.C., Wang G., Conley C., Takeda Y., Conroy S.E., et al. Prolactin levels and antinuclear antibody profiles in women tested for connective tissue disease. Lupus 1996, 5:30-37.
29. Jara L.J., Gomez-Sanchez C., Silveira L.H., Martinez-Osuna P., Vasey F.B., Espinoza L.R. Hyperprolactinemia in SLE: association with disease activity. Am J Med Sci 1992, 303:222-226.
30. Cohen-Solal J.F., Jeganathan V., Grimaldi C.M., Peeva E., Diamond B. Sex hormones and SLE: influencing the fate of autoreactive B cells. Curr Top Microbiol Immunol 2006, 305:67-88.
31. Tedeschi S.K., Bermas B., Costenbader K.H. Sexual disparities in the incidence and course of SLE and RA. Clin Immunol 2013, 149:211-218.
32. Bernier M.O., Mikaeloff Y., Hudson M., Suissa S. Combined oral contraceptive use and the risk of systemic lupus erythematosus. Arthritis Rheum 2009, 61:476-481.
33. Petri M., Kim M.Y., Kalunian K.C., Grossman J., Hahn B.H., Sammaritano L.R., et al. Combined oral contraceptives in women with systemic lupus erythematosus. NEngl J Med 2005, 353:2550-2558.
34. Buyon J.P., Petri M.A., Kim M.Y., Kalunian K.C., Grossman J., Hahn B.H. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005, 142:953-962.
35. Wu W.M., Lin B.F., Su Y.C., Suen J.L., Chang B.L. Tamoxifen deceases renal inflammation and alleviates disease severity in autoimmune NZB/W F1 mice. Scand J Immunol 2000, 52:393-400.
36. Li J., McMurray R.W. Effects of estrogen receptor subtype-selective agonists on autoimmune disease in lupus-prone NZB/W F1 mouse model. Clin Immunol 2007, 132:219-226.
37. Carlsten H., Nilsson N., Jonsson R., Backman K., Holmdahl R., Tarkowski A. Estrogen mediated vasculitis and sialadenitis in autoimmune MRL/lpr mice. Cell Immunol 1992, 144:190-202.
38. Shelly S., Boaz M., Orbach H. Prolactin and autoimmunity. Autoimmun Rev 2012, 11:A465-A470.
39. Leanos A., Pascoe D., Fragra A., Blanco-Favela F. Anti-prolactin autoantibodies in systemic lupus erythematosus patients with associated hyperprolactinemia. Lupus 1998, 7:398-403.
40. Walker S.E. Bromocriptine treatment of systemic lupus erythematosus. Lupus 2001, 10:762-768.
41. McMurray R.W., Weidensaul D., Allen S.H., Walker S.E. Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus. JRheumatol 1995, 22:2084-2091.
42. Alvarez-Nemegyei J., Cobarrubias-Cobos A., Escalante-Triay F., Sosa-Munoz J., Miranda J.M., Jara L.J. Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-conrolled study. Lupus 1998, 7:414-419.
43. McMurray R., Keisler D., Kanuckel K., Izui S., Walker S.E. Prolactin influences autoimmune disease activity in the female B/W mouse. JImmunol 1991, 147:3780-3787.
44. Lee T.P., Chiang B.L. Sex differences in spontaneous versus induced animal models of autoimmunity. Autoimmun Rev 2012, 11:A422-A429.
45. Grimaldi C.M., Michael D.J., Diamond B. Cutting edge: expansion and activation of a population of autoreactive marginal zone B cells in a model of estrogen-induced lupus. JImmunol 2001, 167:1886-1890.
46. Peeva E., Michael D., Cleary J., Rice J., Chen X., Diamond B. Prolactin modulates the naïve B cell repertoire. JClin Invest 2003, 111:275-283.
47. Venkatesh J., Peeva E., Xu X., Diamond B. Cutting edge: hormonal milieu, not antigenic specificity, determines the mature phenotype of autoreactive B cells. JImmunol 2006, 176:3311-3314.
48. Sandel P.C., Monroe J.G. Negative selection of immature B cells by receptor editing or deletion is determined by site of antigen encounter. Immunity 1999, 10:289-299.
49. Wardemann H., Yurasov S., Schaefer A., Young J.W., Meffre E., Nussenzweig M.C. Predominant autoantibody production by early human B cell precursors. Science 2003, 301:1374-1377.
50. Venkatesh J., Yoshifuji H., Kawabata D., Chinnasamy P., Stanevsky A., Grimaldi C.M., et al. Antigen is required for positive selection of pathogenic anti-DNA antibodies and systemic inflammation. JImmunol 2011, 186:5304-5312.
51. Ray S.K., Putterman C., Diamond B. Pathogenic autoantibodies are routinely generated during the response to foreign antigen: a paradigm for autoimmune disease. Proc Natl Acad Sci U S A 1996, 93:2019-2024.
52. Hao Z., Rajewsky K. Homeostasis of peripheral B cells in the absence of B cell influx from the bone marrow. JExp Med 2001, 194:1151-1164.
53. Cunningham M., Gilkeson G. Estrogen receptors in immunity and autoimmunity. Clin Rev Allergy Immunol 2011, 40:66-73.
54. Merrill J.T., Neuwelt C.M., Wallace D.J., Shanahan J.C., Latinis K.M., Oates J.C., et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010, 62:222-233.
55. Astudy to evaluate the efficacy and safety of rituximab in subjects with ISN/RPS class III or IV lupus nephritis (LUNAR) 2010.
56. Grimaldi C.M., Cleary J., Dagtas A.S., Moussai D., Diamond B. Estrogen alters thresholds for B cell apoptosis and activation. JClin Invest 2002, 109:1625-1633.
57. Panchanathan R., Choubey D. Murine BAFF expression is up-regulated by estrogen and interferons: implications for sex bias in the development of autoimmunity. Mol Immunol 2013, 53:15-23.
58. Batten M., Groom J., Cachero T.G., Qian F., Schneider P., Tschopp J., et al. BAFF mediates survival of peripheral immature B lymphocytes. JExp Med 2000, 192:1453-1466.
59. Moulton V.R., Holcomb D.R., Zajdel M.C., Tsokos G.C. Estrogen upregulates cyclic AMP response element modulator α expression and downregulates interleukin-2 production by human T lymphocytes. Mol Med 2012, 18:370-378.
60. Panchanathan R., Duan X., Arumugam M., Shen H., Liu H., Choubey D. Cell type and gender-dependent differential regulation of the p202 and Aim2 proteins: implications for the regulation of innate immune responses in SLE. Mol Immunol 2011, 49:273-280.
61. Cutolo M., Sulli A., Straub R.H. Estrogen metabolism and autoimmunity. Autoimmun Rev 2012, 11:A460-A464.
62. Ledesma-Soto Y., Blanco-Favela F., Fuentes-Pananá E.M., Tesoro-Cruz E., Hernández-González R., Arriaga-Pizano L., et al. Increased levels of prolactin receptor expression correlate with the early onset of lupus symptoms and increased numbers of transitional-1 B cells after prolactin treatment. BMC Immunol 2012, 13:11-24.
63. Desai-Mehta A., Lu L., Ramsey-Goldman R., Datta S.K. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. JClin Invest 1996, 97:2063-2073.
64. Wang X.B., Huang W.Q., Mihara M., Sinha J., Davidson A. Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus. JImmunol 2002, 168:2046-2053.
65. Wang XB, Huang WQ, Schiffer LE, Mihara M, Akkerman A, Hiromatsu K, etal. Effects of anti-CD154 treatment on B cells in murine systemic lupus erythematosus 2003;48:495-506.
66. Boumpas D.T., Furie R., Manzi S., Illei G.G., Wallace D.J., Balow J.E., et al. Ashort course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003, 48:719-727.
67. Mathian A., Gallegos M., Pascual V., Banchereau J., Koutouzov S. Interferon-α induces unabated production of short-lived plasma cells in pre-autoimmune lupus-prone (NZB×NZW)F1 mice but not in BALB/c mice. Eur J Immunol 2011, 41:863-872.
68. Gong Q., Ou Q., Ye S., Lee W.P., Cornelius J., Diehl L., et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. JImmunol 2005, 174:817-826.
69. Yu S., Dunn R., Kehry M.R., Braley-Mullen H. Bcell depletion inhibits spontaneous autoimmune thyroiditis in NOD.H-2h4 mice. JImmunol 2008, 180:7706-7713.
70. Ramanujam M., Wang X., Huang W., Schiffer L., Grimaldi C., Akkerman A., et al. Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. JImmunol 2004, 14:3524-3534.
71. Ramanujam M., Wang X., Huang W., Liu Z., Schiffer L., Tao H., et al. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. JClin Invest 2006, 14:724-734.
72. Mihara M., Tan I., Chuzin Y., Reddy B., Budhai L., Holzer A., et al. CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus. JClin Invest 2000, 106:91-101.